Skip to main content

Advertisement

Table 4 Sensitivity analysis 1 of the relationships between both the eGFR at age 88 years and the decrease in the eGFR 3 years before (between age 85 and 88) and total and cardiovascular (CV) mortality

From: Prediction of mortality and functional decline by changes in eGFR in the very elderly: the Leiden 85-plus study

   eGFR slope per year between 85 and 88 years in ml/min/1.73 m²/year
  >-1 -1 to -2.99 -3 to -4.99 <-5
eGFR at age 88 > 60 (n=169)   n=128 n=26 n=12 n=3
Overall mortality 1 (ref) 1.35 (0.81-2.25) 2.09 (1.07-4.09) 2.43 (0.74-8.03)
CV mortality 1 (ref) 1.12 (0.41-3.08) 3.16 (1.12-8.90) 8.99 (2.34-34.60)
eGFR at age 88 45-59 (n=147)   n=71 n=46 n=21 n=9
Overall mortality 1 (ref) 0.70 (0.43-1.15) 1.07 (0.56-2.05) 2.31 (1.06-5.06)
CV mortality 1 (ref) 0.79 (0.34-1.88) 0.55 (1.39-2.12) 2.87 (0.84-9.82)
eGFR at age 88 < 45 (n=62)   n=20 n=21 n=14 n=7
Overall mortality 1 (ref) 0.60 (0.29-1.23) 0.48 (0.16-1.40) 1.77 (0.52-6.10)
CV mortality 1 (ref) 0.91 (0.34-2.39) 0.31 (0.04-2.42) 4.00 (1.04-15.43)
  1. The results are presented as the HR (95% CI) and were adjusted for the eGFR at age 88 and gender. The results are shown with one reference group for each eGFR subgroup.
  2. * No events.